Jeff - In spite of you and I apparently being the same person, I will answer your question.
We buy 16 shares at $1.05 and then we sell them quickly the same day at $1.10. So we make a nickel per share. On 16 shares that is 80 cents total. Or we could be the entire trading volume and do the same with 416 shares. That would bring our gross profit before commissions and fees to $20.80.
Of course not sure how to be the entire volume of a stock. I guess we can buy and sell to each other, or ourselves since we are one in the same?
Unfortunately we would have to pay the minimum commission and trading fees of say $50 and $3 respectively so we might be losing money on this supposed scheme.
ERB should soon start showing results from all their efforts and corrected fcls. This is going to start getting fun to watch real soon. May is the deadline so int is only a few days away. Watch what happens. When ERB trades up to $3 or $4 a bunch of the folks who post on here will sell. But the real one or wealth generation opportunity is to ride ERB up to $10 +. Not sure as two timing. But does holding a stock a few months longer matter with a reward of 1,000% + gain?
The video about ERB and Suresh was posted on Youtube in January. The only way to find it was to search Youtube. ERB Mannheim posted it on their ERB Mannheim website. Not easy to find. On Youtube it is the only single video posted on the Transasia Youtube channel. I have seen personally other great videos at the ERB booth at trade shows. As usual ERB does the opposite of a "pump". They don't make it obvious. Rather it is hard to find. But it is there. You just have to look.
Just a matter of time till the story gets told and disseminated. In the video you can see where they state clearly 5X growth by 2020. Just think what that means on an annual basis. And look at the growth over the past 5 years for the ERB group. The statement is backed up by the facts and the recent past success.
ERB Manheim owns 83% of ERB (US). The cos are already all working together... Fixing now how they handle accounting before merging them together. Here is what is not yet merged into ERB US:
ERBA Mannheim (Germany)- Recognized as a leading player in the In-vitro diagnostic segment. Through its presence in different countries, ERBA Mannheim provides a comprehensive portfolio in different specialties including clinical chemistry, immunology, hematology, coagulation,critical care, electrophoresis, urine analysis, diabetes monitoring, autoimmune & infectious disease monitoring and microbiology. With a commitment to provide 'Total Solutions in Clinical Diagnosis', each of the ERBA Group companies strive to create a healthier world!
Transasia Bio-Medicals Ltd (India)- Established in 1979, it is a name to reckon in the Indian clinical diagnostics sector, providing end to end solutions in biochemistry, hematology, immunology, critical care, coagulation, urine analysis, electrophoresis, diabetes, microbiology and molecular diagnosis.
ERBA DDS (Turkey)- Established in 1993, the company develops, produces and markets, In-vitro diagnostic products in the field of biochemistry, hematology and urine analysis.
ERBA Lachema s.r.o (Czech Republic)- A company with 40 years tradition in the development, manufacturing and sale of products for urine analysis, clinical chemistry, microbiology & hematology.
ERBA Rus (Russia)- A fast growing marketing company, offering sales and after sales service to its customers in product ranges such as urine analysis, clinical chemistry, microbiology and hematology.
ERBA Diagnostic (France)- The company specializes in conception, design, development and manufacturing of automated analyzers and reagents in the field of clinical chemistry, hemostasis and immunology.
Plus add these 3 (2 ERB US and 1 ERB Manheim) the new businesses ERB US opened in Mexico and Brazil plus latest acquisition Lumora...
Here is what ERB owns 100% already -
ERBA Diagnostics, Inc. (USA)- Fully integrated In-vitro diagnostics company that develops, manufactures and distributes proprietary diagnostic reagents, test kits and instrumentation for autoimmune and infectious diseases in the United States and globally.
Diamedix Corporation (USA)- US FDA approved, it manufactures In-vitro diagnostic kits marketed in conjunction with its MAGO® series instruments for use in clinical and hospital laboratories. Diamedix offers autoimmune and infectious disease test kits of high quality, with containers and customized racks.
JAS Diagnostics Inc. (USA)- Manufacturer of clinical chemistry reagents with sales in USA, Latin America, Africa and Asia. Many of its diagnostic chemistry reagents, are manufactured with in house R&D. JAS Diagnostics provides the laboratories the convenience and stability of state of the art, single vial, liquid stable reagents.
Drew Scientific (USA)- Caters to the field of diabetes management, hematology and clinical chemistry. Its HPLC based HbA1c systems are renowned for their high performance.
ImmunoVision, Inc. (USA)- Based in Arkansas, USA, it develops and manufactures a range of antibodies & antigens for use in diagnostic reagents.
Delta Biologicals, s.r.l. (Italy)- Manufactures the MAGO® range of instruments and distributes In-vitro diagnostic products to public hospitals and private medical laboratories in Italy and other international markets.
"A business based on ethical values is the only business that will last forever"
"After sales service"
"Acquire the latest technology"
At 10:46 - How does he propose to grow 5 times by 2020. Listen carefully. That is 500% for the entire group. That is how you get to $1B in sales. Of course you have to ask how can he possibly grow 500% in 3 years?
Watch the entire video and see if he seems capable, qualified, honest, has the experience...
But as always you have tho invest the time to do the DD necessary to learn. Spend the 23 minutes to watch the video.
I can't post the web address. But if you enter Transasia Bio-Medicals in Youtube and or add "CNBC- Making it Big series: Story of Transasia Transasia Bio-Medicals" you will find it. It is also on the ERB Mannheim site under news.
Try to watch the entire 23 minutes and then figure out how ERB is worth only $1 per share. IMO after you watch the video you will likely understand who Suresh is (his relationship with Ghandi's grandson...) and his plan to combine all the cos together under ERB US and the possibility of ERB growing into a $1B SALES co and the stock being worth $20 per share.
Please let me know your thoughts.
Grand - BTW. ERB's market cap is not 20% of $1B. At $50M or so it is 5% of $1B. You are off by 400%. :)
Not sure where you read that I thought ERB has a $1B market cap? Surely I have said they will have a $1B mkt cap in the future.
Today at $1 per share it will need to trade up to $20 to get to $1B. That is 20X today's price or a 2,000% gain.
Grand - You really have got put Telly, Newport... on Ignore. It is one and the same fellow who posts incessantly on here adding zero value to the conversation. Apparently he believes there is a conspiracy of sorts involved with promoting ERB... He posts so often the same exact delusions of attacking all posters as if they are all one and part of this conspiracy pump and dump theory... Likely he is unbalanced from reading the same posts over and over. By putting his many aliases on Ignore I do not read them anymore now for many years. Those posts pollute the board and I am sure make it unreadable for many.
In any event, what I have posted with regards to ERB and a $1B mkt cap is that they have stated that the ERB goal is to grow organically through increased sales, products, and markets as well as inorganically through mergers and acquisitions of existing ERB related cos and external ones into a $1B co. Not my words. ERB's words. They are speaking about $1B in sales in the future, not market cap. If they achieve that goal they will likely have a market far in excess of $1B by measure of the other comps in med diagnostics. So I think you might have misinterpreted what I posted or I did a poor job of communicating. (would not be the first time)
I have been a shareholder of ERB for well over a decade and posted on this board for that time. Certainly not a short term trader or a pump and dumper... I do believe what ERB says and their progress thus far confirms same. The accounting issue is getting fixed and was discovered by their new CFO who psi over qualified and appears by all accounts to be a great hire for a growing soon to be $100M + public company. For the longer term IMO ERB stock will appreciate to the $10 - $20 range as ERB demonstrates their plan is progressing. Some surely will disagree with my analysis or it may even make them angry. But that is what makes this board valuable in spite of the craziness of the noise from the multi alias conspiracy guy.
I am not exactly sure. I got that off of the PR. I think it is the amount that institutions hold of a particular stock as a percentage of their holdings. I imagine that 271,277 shares of a $1 stock does not register as a full percentage of a Billion $ + institution. That is my guess.
I like that here is a new institution though. The trading volume and float are so tiny it hardly matters.
Newport/telly/ticker - This is an alias I haven't seen you use in a while. Oh well. Add another one to the ignore list. As most times I am cutting and pasting press releases that are online. Hard to argue with facts. But keep trying. Maybe somebody who does not have you on ignore will actually read your post. BTW. They paid cash, not stock so there is no dilution. Maybe in the future when ERB acquires the other ERB cos there will be dilution. But the accretive nature of transactions like that are great for shareholders so we are waiting.
Do you know that ERB trades 5,000 shares a day with a wide spread? It is preposterous under those circumstances for anyone to pump and dump or short term trade ERB. You incessant suggestions that someone is short term trading and or using these boards for same makes you either a fool or deranged. Maybe both? Either way, sorry I did not have that extra ID of your's on ignore and made the mistake to engage you in conversation. I have that one on ignore now along with so many of your other IDs.
I wonder how worried Lumora is about ERB restating some of their old earnings or filing them late? Such a joke.
If my guess is close to right ERB essentially paid in cash close to their market cap for the Lumora acquisition. This also rounds out their portfolio of products entering them into the whole field of molecular diagnostics.
I wonder if it would be likely they would spend $30M in cash to buy another co. getting them into a new and emerging field unless they were planning on growing? Some simple online DD shows the clear path for ERB. The stock will likely react before it is 100% evident.
Lumora acquired by German firm ERBA Diagnostics
Ely's Lumora has been acquired by a German firm. The company, which makes molecular diagnostic products, has been brought by ERBA Diagnostics Mannheim for an undisclosed sum.
"ERBA Diagnostics Mannheim is an excellent home for Lumora's technology," said Laurence Tisi, CEO of Lumora."The company has a strong global presence and is well established in a number of key market segments.
"With the acquisition of Lumora, and its novel technology, ERBA Diagnostics Mannheim is now well placed to expand the use of the technologies globally."
Suresh Vazirani, of ERBA Diagnostics, added: "Lumora has a strong portfolio of molecular technologies which will help us develop molecular testing for emerging country specific diseases such as HIV.
Blackrock Institutional Trust Company N.A. has 0% invested in the company for 271,277 shares. The New Jersey-based Blackrock Investment Management Llc has invested 0% in the stock. Bridgeway Capital Management Inc, a Texas-based fund reported 24,996 shares.
From Bridgeway -
"We seek to avoid personal biases and human emotions in the decision-making process. We focus on objective data gathered from multiple sources over decades and through multiple market cycles.
Bridgeway’s investment process features these attributes:
Statistically driven and evidence-based
Grounded in academic theory
Innovative product design
Strict adherence to investment objectives
Efficient trade execution"
That is very accurate analysis. Kass (the activist) is 6 successes out of 7 tries to take over boards and sell the company. I think he will succeed with this POS. While it is micro in nature the ROI can still be very high albeit on a small amount of capital. I don't own TKOI. Just using it as an example of another Milwaukee tiny clean tech type co like ZBB that missed while TSLA and others have succeeded.
Really feeling strong about ERB. The ground game in terms of their products and growth plans is all ramping while at the same time the ERB stock price reflects a BK co or worse. Makes no sense. But I understand in micro cap land it can happen in the short run. However longer term the fundamentals catch up.
You really should do a little DD on Suresh to see what he has already done in creating wealth with med diagnostics with Transavia and ERB Mannheim. He started with $5 and has grown organically and through acquisitions into a several hundred million $ business. Now he is planning on ramping the growth putting it all under the ERB public co to use the stock to move things along even faster. Maybe not fast enough for some short term players. But the upside is a Peter Lynch 20 bagger. Hard to see any downside trading below asset value. All IMO
It is very much the haves and the have nots. Look at TKOI. Another Milwaukee based energy savings type business like ZBB. It is trading below asset value as if it will go out of business. And this one actually generates a little positive cash flow with probably $20M in sales this year. NOL of $88M and a mkt cap of $22M.
An activist investor is launching a proxy fight to take over the board and sell the co. Already announced. He is 6 out 7 as a success rate. So I guess he will win. Probably worth more in a sale than it is trading at. Who knows?
My point is look a Tesla and its success and mkt cap compared to other energy innovators. Musk is magic - Pay Pal, Solar City, Spacex, TSLA...Eric is no Elon.
Form over substance. EVs are great and I have one. TSLAs are too expensive currently but the new model 3 can be a game changer. BUT here are a couple potential road bumps - no pun intended:
The $7,500 rebate goes a far way to making them economical. That is only good for the first 200,000 cars. With tens of thousands already sold plus the new models coming before the launch of model 3s it is unclear whether the rebate will be there or how much. Elimination of the rebate will essentially add $7,500 to the cost. Same3 for state incentives.
If history is an indication they will have more delays and it will not scale or launch on time. Good for marketing but bad longer term as the economics get worse rather than better.
The competition is not asleep - Nissan, BMW, Fiat, GM... Wait till you see what they are going up with. Unclear TSLA can compete once they go mass market with the model 3.
Grid implications. Yes. But opportunities as well. The EV is essentially a moving storage system. Peak shaving, load shifting, demand response... That is all coming and will help for distributed generation. Cvs charge at night when the grid is not used and power is being wasted....
There are some that think ERB's ability to test quickly, accurately and inexpensively A1c on site is a game changer. All of the time and revenue lost by sending outsourcing samples to a lab can be gained by Doc offices, smaller hospitals, points of care... It will be interesting to see what countries are already using the Hb Vario and what ERB's plans for rolling out are.
If a new one product co. went public or raised capital with just the one product being the Hb Vario I wonder what the valuation would be? Certainly a lot more than where ERB is trading now. But ERB has a lot more than just the one product. When people fully appreciate and figure it out the stock will adjust. And that can happen overnight.
The RE deal is frankly just lucky for ERB. Right place at the right time. And it is nonrecurring. But any public co that will generate tens of millions of dollars from an unused asset they sale is found money.
Maybe if you go just look at one product like the Hb Vario. That would be quick and pretty easy to evaluate. It is a diabetes (blood sugar) test. Brand new equipment and test kits. They claim it is a better mouse trap. Lower cost, smaller footprint, easier to administer requiring less labor expense, faster results... Opens up a whole new and large market Diabetes is a multi billion $ market. The product is already out and if you look at the Medica Show website it is front and center on their website as a featured product. IMO that one product is worth $5 per ERB share longer term.
That 2140 N Miami address is the old address. That is the property ERB still owns and is selling. The area is now the Wynwood Art District. You should go see that property since ERB owns it with no debt and is selling it for around $1 per share or +- $30M. The RE represents close to $1 a share in cash so it is material.
That old property is only a quarter the size of the new facility. Or put another way, the new facility/HQ is 4X the size of their old place. The new place is across from the Executive Airport in Miami Lakes -
ERBA Diagnostics Inc.
14100 NW 57th Court
Miami Lakes, FL 33014
If you really go there, stop in, visit with Mohan and team, and look at their operation. Come back on this board and let us know what you think. That would be value add. Something that is lacking on this board.
The ignore button cancels out the multi alias crazy guy. But there are so many nonsense posts from him, it is a distraction.
I bet Eric will turn up somewhere. One day storage will get there. Sure is a long time in coming.
Like many things. With enough perspective and a longer term view things become more clear. Juts like the crazy screaming in the background here, Just noise. it is good to see through the short term noise.
Currently in the short term with ERB this accounting nonsense is just a little noise. Expect longer term for good things to happen with ERB. Actually believe they have a shot to get to their promised $1B in sales. If that happens ERB will have the best buy I have seen at these prices. If ERB does not ever et to their $1B goal I still believe the stock will see $5 or $10 as they make the effort. Cant see much downside assuming they continue forward as promised.
You are correct ERB is not desperate to sell the RE. They initially had it under contract for around $23M if I remember correctly.
By not doing that deal and waiting even this short amount of time the RE is now IMO worth well over $30M based on recent sales in Wynwood. Many on here have said management is not smart or dishonest... This so far has been a genius move to wait.
But Suresh just put in an additional $3M of his own cash into ERB. Clearly ERB is planning to merge the other cos in as well as make acquisitions as they have stated many times. That will surely require at least some cash. So he does in fact need the money from the RE.
Additionally while it is true the values and activity have literally sky rocketed in Wynwood. The buildings are now completely empty since ERB has moved to their new and much larger location. ERB is not in the RE business and will sell the property. But as a med diagnostic co they are certainly brilliant so far with their RE acumen. Or maybe just crazy lucky. Either way Ill take it.
In my analysis ERB is currently trades at or below just the RE value alone. Giving zero value to the business, products, inventory, patents, FDA approvals, customers, assets (no material liabilities)... Looks great here.